{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T02:54:09Z","timestamp":1780109649346,"version":"3.54.0"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ejphar.2024.177110","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T11:09:43Z","timestamp":1731582583000},"page":"177110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Innovative hypertension treatments: Transitioning from conventional therapies to siRNA-based solutions"],"prefix":"10.1016","volume":"985","author":[{"given":"Reza","family":"Parvan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph Pierre","family":"Aboumsallem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3287-6766","authenticated-orcid":false,"given":"Wouter C.","family":"Meijers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"De Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.H. Jan","family":"Danser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2024.177110_bib1","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ejphar.2024.177110_bib2","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s40256-023-00605-5","article-title":"The pivotal role of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in hypertension management and cardiovascular and renal protection: a critical appraisal and comparison of international guidelines","volume":"23","author":"Alcocer","year":"2023","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.ejphar.2024.177110_bib3","article-title":"Mechanisms and clinical implications of endothelial dysfunction in arterial hypertension","volume":"9","author":"Ambrosino","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"key":"10.1016\/j.ejphar.2024.177110_bib4","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1001\/jama.2024.0728","article-title":"RNA interference with zilebesiran for mild to moderate hypertension: the KARDIA-1 randomized clinical trial","volume":"331","author":"Bakris","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2024.177110_bib5","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.pcad.2016.10.002","article-title":"Renin angiotensin aldosterone system inhibitors in hypertension: is there evidence for benefit independent of blood pressure reduction?","volume":"59","author":"Bavishi","year":"2016","journal-title":"Prog. Cardiovasc. Dis."},{"key":"10.1016\/j.ejphar.2024.177110_bib6","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1161\/HYPERTENSIONAHA.123.21156","article-title":"NGAL is a novel target in hypertension by modulating the NCC-mediated renal Na balance","volume":"80","author":"Bonnard","year":"2023","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2024.177110_bib7","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1161\/HYPERTENSIONAHA.114.03575","article-title":"Endothelial dysfunction and hypertension","volume":"64","author":"Brandes","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2024.177110_bib8","series-title":"Pharmacotherapy of Pulmonary Hypertension","first-page":"161","article-title":"Calcium-Channel blockers in pulmonary arterial hypertension","author":"Chaumais","year":"2013"},{"key":"10.1016\/j.ejphar.2024.177110_bib9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1161\/HYPERTENSIONAHA.113.01766","article-title":"Role of GRK4 in the regulation of arterial AT1 receptor in hypertension","volume":"63","author":"Chen","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2024.177110_bib10","article-title":"Clinical efficacy and safety of spironolactone in patients with resistant hypertension: a systematic review and meta-analysis","volume":"99","author":"Chen","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.ejphar.2024.177110_bib11","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/HYP.0000000000000203","article-title":"Medication adherence and blood pressure control: a scientific statement from the American heart association","volume":"79","author":"Choudhry","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2024.177110_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ph15050575","article-title":"Biotechnological evolution of siRNA molecules: from bench tool to the refined drug","author":"de Brito e Cunha","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejphar.2024.177110_bib13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2208391","article-title":"Zilebesiran, an RNA interference therapeutic agent for hypertension","volume":"389","author":"Desai Akshay","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2024.177110_bib14","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41371-018-0138-y","article-title":"A systematic review and network meta-analysis of the comparative efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertension","volume":"33","author":"Dimou","year":"2019","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.ejphar.2024.177110_bib15","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1007\/s00467-022-05802-z","article-title":"Endothelial dysfunction as a factor leading to arterial hypertension","volume":"38","author":"Dro\u017cd\u017c","year":"2023","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.ejphar.2024.177110_bib16","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1751-7176.2011.00513.x","article-title":"Calcium channel blockers","volume":"13","author":"Elliott","year":"2011","journal-title":"J. Clin. Hypertens."},{"key":"10.1016\/j.ejphar.2024.177110_bib27","first-page":"605","article-title":"Changes of neutrophil gelatinase-associated lipocalin in patients with primary hypertension and its clinical significance","volume":"34","author":"Fei","year":"2013","journal-title":"J. Capi. Med. Unive."},{"key":"10.1016\/j.ejphar.2024.177110_bib17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(13)61914-5","article-title":"Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial","volume":"383","author":"Fitzgerald","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2024.177110_bib18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2024.177110_bib19","author":"Foster"},{"key":"10.1016\/j.ejphar.2024.177110_bib20","author":"Frederic"},{"key":"10.1016\/j.ejphar.2024.177110_bib21","doi-asserted-by":"crossref","DOI":"10.2215\/CJN.14730920","article-title":"Phase 1\/2 study of lumasiran for treatment of primary hyperoxaluria type 1: a placebo-controlled randomized clinical trial","volume":"16","author":"Frishberg","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2024.177110_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104587","article-title":"\u03b2-blockers: their new life from hypertension to cancer and migraine","volume":"151","author":"Fumagalli","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2024.177110_bib23","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nbt.2612","article-title":"Image-based analysis of lipid nanoparticle\u2013mediated siRNA delivery, intracellular trafficking and endosomal escape","volume":"31","author":"Gilleron","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejphar.2024.177110_bib24","series-title":"Pediatric Hypertension","first-page":"205","article-title":"Endothelial dysfunction and vascular remodeling in hypertension","author":"Goodwin","year":"2018"},{"key":"10.1016\/j.ejphar.2024.177110_bib25","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.2147\/PPA.S368784","article-title":"A critical review of medication adherence in hypertension: barriers and facilitators clinicians should consider","volume":"16","author":"Hamrahian","year":"2022","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.ejphar.2024.177110_bib26","article-title":"Predicting heart failure with preserved and reduced ejection fraction: the international collaboration on heart failure subtypes","volume":"9","author":"Ho","year":"2016","journal-title":"Circulation: Heart Fail."},{"key":"10.1016\/j.ejphar.2024.177110_bib28","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2024.177110_bib29","author":"Jian"},{"key":"10.1016\/j.ejphar.2024.177110_bib30","author":"Jun"},{"key":"10.1016\/j.ejphar.2024.177110_bib31","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12929-023-00981-9","article-title":"Small interfering RNA (siRNA)-based therapeutic applications against viruses: principles, potential, and challenges","volume":"30","author":"Kang","year":"2023","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ejphar.2024.177110_bib32","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/CIRCULATIONAHA.120.049730","article-title":"Nighttime blood pressure phenotype and cardiovascular prognosis","volume":"142","author":"Kario","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2024.177110_bib33","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s41440-024-01622-w","article-title":"The WHO Global report 2023 on hypertension warning the emerging hypertension burden in globe and its treatment strategy","volume":"47","author":"Kario","year":"2024","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.ejphar.2024.177110_bib34","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1056\/NEJMp1614154","article-title":"Oligonucleotide therapeutics\u2014a new class of cholesterol-lowering drugs","volume":"376","author":"Khvorova","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2024.177110_bib35","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/ejhf.945","article-title":"A comprehensive population-based characterization of heart failure with mid-range ejection fraction","volume":"19","author":"Koh","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ejphar.2024.177110_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25074035","article-title":"Renin\u2013angiotensin\u2013aldosterone system: from history to practice of a secular topic","author":"Ksiazek","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.177110_bib37","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1161\/HYPERTENSIONAHA.111.187872","article-title":"Neutrophil gelatinase-associated lipocalin is a novel mineralocorticoid target in the cardiovascular system","volume":"59","author":"Latouche","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2024.177110_bib38","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1161\/HYPERTENSIONAHA.120.16784","article-title":"Adherence to antihypertensive medication and incident cardiovascular events in young adults with hypertension","volume":"77","author":"Lee","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2024.177110_bib39","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1161\/ATVBAHA.111.230623","article-title":"Moderate caveolin-1 downregulation prevents NADPH oxidase\u2013dependent endothelial nitric oxide synthase uncoupling by angiotensin II in endothelial cells","volume":"31","author":"Lobysheva","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejphar.2024.177110_bib40","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41392-023-01430-7","article-title":"Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions","volume":"8","author":"Ma","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2024.177110_bib41","doi-asserted-by":"crossref","first-page":"f360","DOI":"10.1136\/bmj.f360","article-title":"Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials","volume":"346","author":"Makani","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.ejphar.2024.177110_bib42","doi-asserted-by":"crossref","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"Mancia","year":"2023","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ejphar.2024.177110_bib43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/eurjpc\/zwac163","article-title":"Non-pharmacological factors for hypertension management: a systematic review of international guidelines","volume":"30","author":"Maniero","year":"2023","journal-title":"Eur. J. Preven. Cardiol."},{"key":"10.1016\/j.ejphar.2024.177110_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2024.102411","article-title":"Unraveling the complex pathophysiology of heart failure: insights into the role of renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS)","volume":"49","author":"Maryam","year":"2024","journal-title":"Curr. Probl. Cardiol."},{"key":"10.1016\/j.ejphar.2024.177110_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2023.1034170","article-title":"Role of the renin-angiotensin system in the pathophysiology of coronary heart disease and heart failure: diagnostic biomarkers and therapy with drugs and natural products","volume":"14","author":"Mehta","year":"2023","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ejphar.2024.177110_bib46","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1161\/HYPERTENSIONAHA.117.09755","article-title":"Blood pressure lowering and safety improvements with liver angiotensinogen inhibition in models of hypertension and kidney injury","volume":"70","author":"Mullick","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2024.177110_bib47","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfae058","article-title":"Proximal versus distal diuretics in congestive heart failure","author":"Nardone","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ejphar.2024.177110_bib48","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nrneph.2011.29","article-title":"Limitations of angiotensin inhibition","volume":"7","author":"Nobakht","year":"2011","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ejphar.2024.177110_bib49","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/hr.2013.155","article-title":"Targeting of hepatic angiotensinogen using chemically modified siRNAs results in significant and sustained blood pressure lowering in a rat model of hypertension","volume":"37","author":"Olearczyk","year":"2014","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.ejphar.2024.177110_bib50","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/clc.23303","article-title":"Hypertension in older adults: assessment, management, and challenges","volume":"43","author":"Oliveros","year":"2020","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.ejphar.2024.177110_bib51","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1161\/HYPERTENSIONAHA.120.15781","article-title":"Adherence to single-pill versus free-equivalent combination therapy in hypertension","volume":"77","author":"Parati","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2024.177110_bib52","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ijcard.2021.01.070","article-title":"Current challenges for hypertension management: from better hypertension diagnosis to improved patients' adherence and blood pressure control","volume":"331","author":"Parati","year":"2021","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ejphar.2024.177110_bib53","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2024.177110_bib54","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1096\/fj.07-8424com","article-title":"Increased smooth muscle cell expression of caveolin-1 and caveolae contribute to the pathophysiology of idiopathic pulmonary arterial hypertension","volume":"21","author":"Patel","year":"2007","journal-title":"Faseb. J."},{"key":"10.1016\/j.ejphar.2024.177110_bib55","author":"Ping"},{"key":"10.1016\/j.ejphar.2024.177110_bib56","doi-asserted-by":"crossref","DOI":"10.1097\/HJH.0000000000002294","article-title":"Medication adherence in hypertension","volume":"38","author":"Poulter","year":"2020","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ejphar.2024.177110_bib57","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1748-1716.2008.01907.x","article-title":"The role of caveolin-1 in cardiovascular regulation","volume":"195","author":"Rahman","year":"2009","journal-title":"Acta Physiol."},{"key":"10.1016\/j.ejphar.2024.177110_bib58","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1038\/s41591-022-01974-1","article-title":"Effects of elevated systolic blood pressure on ischemic heart disease: a Burden of Proof study","volume":"28","author":"Razo","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2024.177110_bib59","article-title":"First\u2010line diuretics versus other classes of antihypertensive drugs for hypertension","author":"Reinhart","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejphar.2024.177110_bib60","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1161\/CIRCRESAHA.116.303587","volume":"116","author":"Riet","year":"2015","journal-title":"Hyperten. Circula. Res."},{"key":"10.1016\/j.ejphar.2024.177110_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2018.00082","article-title":"Role of the sympathetic nervous system and its modulation in renal hypertension","volume":"5","author":"Sata","year":"2018","journal-title":"Front. Med."},{"key":"10.1016\/j.ejphar.2024.177110_bib62","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1097\/HJH.0000000000003215","article-title":"Use of initial and subsequent antihypertensive combination treatment in the last decade: analysis of a large Italian database","volume":"40","author":"Savar\u00e9","year":"2022","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ejphar.2024.177110_bib63","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2012.10.011","article-title":"A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure","volume":"61","author":"Savarese","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2024.177110_bib64","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2022","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2024.177110_bib65","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2024.177110_bib66","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1161\/CIRCRESAHA.120.318729","article-title":"Hypertension in low- and middle-income countries","volume":"128","author":"Schutte","year":"2021","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2024.177110_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/pharmacy12020058","article-title":"A comparison of currently approved small interfering RNA (siRNA) medications to alternative treatments by costs, indications, and medicaid coverage","author":"Sehgal","year":"2024","journal-title":"Pharmacy"},{"key":"10.1016\/j.ejphar.2024.177110_bib68","doi-asserted-by":"crossref","first-page":"8259","DOI":"10.1080\/21655979.2021.1982846","article-title":"Role of adaptin protein complexes in intracellular trafficking and their impact on diseases","volume":"12","author":"Shin","year":"2021","journal-title":"Bioengineered"},{"key":"10.1016\/j.ejphar.2024.177110_bib69","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/clc.23938","article-title":"Management of arterial hypertension: challenges and opportunities","volume":"45","author":"Silva","year":"2022","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.ejphar.2024.177110_bib70","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study","volume":"10","author":"Suhr","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ejphar.2024.177110_bib71","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/hr.2011.105","article-title":"The central mechanism underlying hypertension: a review of the roles of sodium ions, epithelial sodium channels, the renin\u2013angiotensin\u2013aldosterone system, oxidative stress and endogenous digitalis in the brain","volume":"34","author":"Takahashi","year":"2011","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.ejphar.2024.177110_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176467","article-title":"siRNA as potential therapeutic strategy for hypertension","volume":"969","author":"Tanna","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177110_bib73","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1097\/HJH.0000000000002523","article-title":"Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials","volume":"38","author":"Thomopoulos","year":"2020","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ejphar.2024.177110_bib74","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/HJH.0000000000002759","article-title":"Monotherapy vs combination treatments of different complexity: a meta-analysis of blood pressure lowering randomized outcome trials","volume":"39","author":"Thomopoulos","year":"2021","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ejphar.2024.177110_bib75","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1124\/jpet.122.001234","article-title":"RNAi-based therapeutics and novel RNA bioengineering technologies","volume":"384","author":"Traber","year":"2023","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2024.177110_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12206486","article-title":"The sympathetic nervous system in hypertensive heart failure with preserved LVEF","author":"Triposkiadis","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejphar.2024.177110_bib77","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1161\/HYPERTENSIONAHA.119.12703","article-title":"Strong and sustained antihypertensive effect of small interfering RNA targeting liver angiotensinogen","volume":"73","author":"Uijl","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2024.177110_bib78","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026426","article-title":"Conventional vasopressor and vasopressor\u2010sparing strategies to counteract the blood pressure\u2013lowering effect of small interfering RNA targeting angiotensinogen","volume":"11","author":"Uijl","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ejphar.2024.177110_bib79","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40120-020-00208-1","article-title":"A review of patisiran (ONPATTRO\u00ae) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis","volume":"9","author":"Urits","year":"2020","journal-title":"Neurol Ther"},{"key":"10.1016\/j.ejphar.2024.177110_bib80","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCRESAHA.117.311402","article-title":"Hypertension and atrial fibrillation","volume":"122","author":"Verdecchia","year":"2018","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2024.177110_bib81","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","article-title":"A new taxonomy for describing and defining adherence to medications","volume":"73","author":"Vrijens","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177110_bib82","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1161\/HYPERTENSIONAHA.115.05962","article-title":"Human GRK4\u03b3142V variant promotes angiotensin II type I receptor-mediated hypertension via renal histone deacetylase type 1 inhibition","volume":"67","author":"Wang","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2024.177110_bib83","article-title":"Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension","author":"Wang","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejphar.2024.177110_bib84","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/jamacardio.2023.0720","article-title":"Efficacy and safety of low-dose triple and quadruple combination pills vs monotherapy, usual care, or placebo for the initial management of hypertension: a systematic review and meta-analysis","volume":"8","author":"Wang","year":"2023","journal-title":"JAMA Cardiology"},{"issue":"7571","key":"10.1016\/j.ejphar.2024.177110_bib85","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1136\/bmj.333.7571.717","article-title":"Work on RNA interference brings Nobel triumph","volume":"333","author":"Watts","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.ejphar.2024.177110_bib86","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.21618","article-title":"Comparison of cardiovascular events among users of different classes of antihypertension medications: a systematic review and network meta-analysis","volume":"3","author":"Wei","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ejphar.2024.177110_bib87","author":"Wei"},{"key":"10.1016\/j.ejphar.2024.177110_bib88","series-title":"Global Report on Hypertension: the Race against a Silent Killer","first-page":"1","year":"2023"},{"key":"10.1016\/j.ejphar.2024.177110_bib89","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2024.177110_bib90","author":"Woong"},{"key":"10.1016\/j.ejphar.2024.177110_bib91","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jacc.2023.10.007","article-title":"Safety and tolerability of inclisiran for treatment of hypercholesterolemia in 7 clinical trials","volume":"82","author":"Wright","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2024.177110_bib92","doi-asserted-by":"crossref","first-page":"183","DOI":"10.7156\/v4i4p183","article-title":"Molecular and pathophysiological features of angiotensinogen: a mini review","volume":"4","author":"Wu","year":"2011","journal-title":"N. Am. J. Med. Sci."},{"key":"10.1016\/j.ejphar.2024.177110_bib93","author":"Xiaoyong"},{"key":"10.1016\/j.ejphar.2024.177110_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108194","article-title":"Comprehensive insights in GRK4 and hypertension: from mechanisms to potential therapeutics","volume":"239","author":"Yang","year":"2022","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.ejphar.2024.177110_bib95","author":"Ye"},{"key":"10.1016\/j.ejphar.2024.177110_bib96","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1042\/CS20200671","article-title":"GRK4-mediated adiponectin receptor-1 phosphorylative desensitization as a novel mechanism of reduced renal sodium excretion in hypertension","volume":"134","author":"Zhang","year":"2020","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.ejphar.2024.177110_bib97","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","author":"Zhou","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2024.177110_bib98","article-title":"Calcium channel blockers versus other classes of drugs for hypertension","author":"Zhu","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejphar.2024.177110_bib99","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nbt.4136","article-title":"Reversal of siRNA-mediated gene silencing in vivo","volume":"36","author":"Zlatev","year":"2018","journal-title":"Nat. Biotechnol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924008008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924008008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T01:29:40Z","timestamp":1733621380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299924008008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":99,"alternative-id":["S0014299924008008"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.177110","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovative hypertension treatments: Transitioning from conventional therapies to siRNA-based solutions","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.177110","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"177110"}}